Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...

Recently published study focused on the evaluation of a novel etomidate analogue, methoxyethyl etomidate hydrochloride (ET-26), in healthy volunteers to assess its safety, tolerability, ...

"The Evrysdi tablet combines established efficacy with convenience, providing an additional flexible option for SMA management." The approval of the Evrysdi tablet was based on the results of a ...

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics ...

By Tarun Sai Lomte A study finds that IN-006, a reformulated monoclonal antibody, is safe, well-tolerated, and delivers high ...

Silo Pharma (NASDAQ: SILO) announced encouraging early results from its ongoing study evaluating the pharmacokinetics, safety and tolerability of it ...

Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...

NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company with a market capitalization of $32.36 million, has initiated a Phase 2 clinical trial for RLYB212, a ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, ...